Innovent Releases Phase 2 Results of Pemigatinib in Chinese Patients with Advanced Cholangiocarcinoma at ESMO Congress 2021
SAN FRANCISCO and SUZHOU, China, Sept. 17, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced that the results of the Phase 2 study in Chinese patients with advanced cholangiocarcinoma were released today at the European...
CStone will present registrational clinical study data of Sugemalimab in patients with stage III non-small cell lung cancer in an oral presentation at ESMO Congress 2021
Sugemalimab is the world's first anti-PD-1/PD-L1 monoclonal antibody to significantly improve progression-free survival (PFS) in patients with stage III non-small cell lung cancer (NSCLC) without disease progression after concurrent or sequential chemoradiotherapy The data showed that sugemalimab demonstrated a statistically significant and clinically meaningful improvement in the Blinded Independent Central Review (BICR) assessed PFS. The risk of...
Everest Medicines, Sinovent and SinoMab Announce Licensing Agreement for Global Development, Manufacturing and Commercialization of Novel BTK Inhibitor in Renal Diseases
SHANGHAI, Sept. 17, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest") announced today that it has entered into an exclusive licensing agreement with Suzhou Sinovent Pharmaceuticals Co., Ltd. ("Sinovent") and SinoMab BioScience Limited (stock code: 3681.HK "SinoMab") to develop, produce and commercialize XNW1011 (referred as "SN1011" by SinoMab), a covalent reversible Bruton's tyrosine kinase (BTK) inhibitor, globally for the treatment...
Bridge Biotherapeutics Presents Pre-Clinical Data of BBT-176 at the European Society for Medical Oncology (ESMO) Virtual Congress 2021
Pre-clinical data exploring the in vitro and in vivo efficacy of BBT-176 will be disclosed via an ePoster at the ESMO Congress 2021 Patient dosing for the phase 1/2 clinical study of BBT-176 was initiated in April 2021…the topline data of the first-in-human, dose escalation study is expected to be announced in 2022 SEONGNAM,...
PharmaZell and Novasep enter into exclusive negotiations in new drive to create a technology-driven leader for complex small molecules and ADCs of global scale
RAUBLING, Germany and LYON, France, Sept. 17, 2021 /PRNewswire/ -- PharmaZell, the German producer of highly resilient and specialty APIs, and France-based Novasep, a leading CDMO focused on complex small molecules and ADCs have entered into exclusive negotiations to create a leading European platform in the attractive API manufacturing and CDMO space with...
Satisfai Health acquires global license for AI software to detect early cancer in Barrett’s Esophagus
Advanced real-time clinical diagnostics for up to 150 million people VANCOUVER, BC, Sept. 16, 2021 /PRNewswire/ -- Satisfai Health, a leading medical solutions provider specializing in artificial intelligence (AI) applications, particularly in Gastrointestinal Endoscopy, has acquired an exclusive global license from the University of Augsburg and the OTH Regensburg, Technical University of Applied...
Syapse Awarded 2021 Technology Innovation Leadership Award by Frost & Sullivan for Accelerating Real-world Care Delivery
Syapse's three-pronged approach offers a complete service cycle, helping health systems, providers, and life science organizations to improve cancer care quality SANTA CLARA, Calif., Sept. 16, 2021 /PRNewswire/ -- Based on its recent analysis of the global oncology data-sharing software platform market, Frost & Sullivan recognizes Syapse, Inc (Syapse) with the 2021 Global Technology Innovation Leadership Award in the...
Validic Empowers Physicians and Care Managers to Manage Personal Health Data at Scale
Validic's best-in-class strategy is supported by its deep integration into clinical workflows and care pathways and its simple application design for consumer engagement SANTA CLARA, Calif., Sept. 16, 2021 /PRNewswire/ -- Based on its recent analysis of the North American remote patient monitoring (RPM) market, Frost & Sullivan recognizes Validic, Inc. with the...
Tom Golisano Gifts $30 Million to Special Olympics to Expand Critical Health Services Globally for People with Intellectual Disabilities
WASHINGTON, Sept. 16, 2021 /PRNewswire/ -- Special Olympics announced today that it has received its largest single private gift in the organization's 53-year history. Tom Golisano, Paychex founder, philanthropist and father of a son with an intellectual disability, will provide $30 million, his third major gift to Special Olympics, to expand the Special Olympics Healthy Communities program, which provides health services...
COVID-19 Scoop: Epoch-Making GoldenBiotech’s Oral COVID-19 New Drug Trial Got Green Light from the FDA to Extend Recruiting Severe COVID-19 Patients
TAIPEI, Sept.16, 2021 /PRNewswire/ -- Golden Biotechnology Corp.(TPEx:4132) ("GoldenBiotech", GBC), a leading Taiwanese biopharmaceutical company, announces that its oral investigational new drug Antroquinonol (HOCENA®) has made headway with COVID-19 treatment development in more broaden clinical trial patients permitted in inclusion severity as well as future marketing expansion by signing a new international MOU for cooperation and development of...
